Psilocybin’s potential benefits and risks for bipolar depression

Declarations. Conflicts of Interest: BS has received research grant support from Mayo Clinic, the National Network of Depression Centers, Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2), and the NIH. He is a KL2 Mentored Career Development Program scholar, supported by Clinical and Translational Science Award grant number KL2 TR002379 from the NCATS. He has received honoraria (to the Mayo Clinic) from Elsevier for editing a clinical overview on treatment-resistant depression. MGM and LP have no competing interests to disclose. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Funding sources had no role in the production of this manuscript. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent to Publish: Not applicable. Availability of Data and Material: Not applicable. Code Availability: Not applicable. Author’s Contributions: All authors contributed to the concept and design, drafting of the manuscript, critical revision of the manuscript for important intellectual content. The authors agree to be accountable for the work.